Literature DB >> 7109582

In vitro biotransformation of glucocorticoids in liver and skin homogenate fraction from man, rat and hairless mouse.

P Andersson, S Edsbäcker, A Ryrfeldt, C von Bahr.   

Abstract

The pharmacological effects of glucocorticoids are greatly influenced by their pharmacokinetic properties. In the present report, the in vitro biotransformation of the topical glucocorticoids [3H]-budesonide ([3H]-BUD). [3H]-triamcinolone acetonide ([3H]-TAAc) and [3H]-hydrocortisone ([3H]-HC) was studied in the 9000 g liver and skin supernatant from man, rat and hairless mouse. The rate of disappearance of the compounds was estimated during the initial 30 min of incubation by high performance liquid chromatography. In human liver the half life (t1/2) rank order was [3H]-BUD (7--23 min) less than [3H]-TAAc (13--68 min) less than [3H]-HC (40--67 min), in rat liver [3H]-HC (14--21 min) less than [3H]-BUD (28--38 min) less than [3H]-TAAc (161--196 min) and in hairless mouse liver [3H]-BUD (17--22 min) less than [3H]-TAAc (21--34 min) less than [3H]-HC (82--165 min). Negligible biotransformation of these glucocorticoids occurred in skin. BUD is a one to one mixture of the [22R]- and [22S]-epimers. It was found that the [22R]-epimer was more susceptible to liver biotransformation than the [22S]-epimer of [3H]-BUD. The results are discussed with particular reference to the extent of systemic side effects of these compounds.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7109582     DOI: 10.1016/0022-4731(82)90036-x

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  6 in total

1.  Pharmacokinetics of budesonide in children with asthma.

Authors:  S Pedersen; G Steffensen; I Ekman; M Tönnesson; O Borgå
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases.

Authors:  M Scudeletti; F Puppo; L Lanza; L Mantovani; O Bosco; A Iudice; B Imbimbo; F Indiveri
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man.

Authors:  S A Johansson; K E Andersson; R Brattsand; E Gruvstad; P Hedner
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man.

Authors:  S Edsbäcker; K E Andersson; A Ryrfeldt
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 5.  Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis.

Authors:  S P Clissold; R C Heel
Journal:  Drugs       Date:  1984-12       Impact factor: 9.546

6.  Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis.

Authors:  David T Rubin; William J Sandborn; Brian Bosworth; Salam Zakko; Glenn L Gordon; Mark E Sale; Robert L Rolleri; Pamela L Golden; Andrew C Barrett; Enoch Bortey; William P Forbes
Journal:  Dig Dis Sci       Date:  2015-09-19       Impact factor: 3.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.